TICKERNOMICS Sign up
Last Update: 2024-12-27 15:27:31
ATOSSA THERAPEUTICS INC. ( ATOS ) https://www.atossatherapeutics.com
1.06USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
ATOS
8.60%
SPY
32.66%
-36.14%
ATOS
SPY
108.59%
-36.34%
ATOS
SPY
302.52%
-99.54%
ATOS
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
133.32
58.55
1.01
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-4.95
-71.93
1.81
-11.20
0.00
-2.18
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-39472.22
-22.22
-37275.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
10.2816
-10.42
-25.70
1.62
Other Earnings and Cash Flow Stats:
ATOSSA THERAPEUTICS INC. ( ATOS ) Net Income TTM ($MM) is -26.91
ATOSSA THERAPEUTICS INC. ( ATOS ) Operating Income TTM ($MM) is -29.49
ATOSSA THERAPEUTICS INC. ( ATOS ) Owners' Earnings Annual ($MM) is 0.00
ATOSSA THERAPEUTICS INC. ( ATOS ) Current Price to Owners' Earnings ratio is 0.00
ATOSSA THERAPEUTICS INC. ( ATOS ) EBITDA TTM ($MM) is -29.46
ATOSSA THERAPEUTICS INC. ( ATOS ) EBITDA Margin is -37275.00%
Capital Allocation:
ATOSSA THERAPEUTICS INC. ( ATOS ) has paid 0.00 dividends per share and bought back 0.020336 million shares in the past 12 months
ATOSSA THERAPEUTICS INC. ( ATOS ) has increased its debt by 0.0 million USD in the last 12 months
Capital Structure:
ATOSSA THERAPEUTICS INC. ( ATOS ) Interest-bearing Debt ($MM) as of last quarter is 0
ATOSSA THERAPEUTICS INC. ( ATOS ) Annual Working Capital Investments ($MM) are 0
ATOSSA THERAPEUTICS INC. ( ATOS ) Book Value ($MM) as of last quarter is 73
ATOSSA THERAPEUTICS INC. ( ATOS ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
ATOSSA THERAPEUTICS INC. ( ATOS ) has 74 million in cash on hand as of last quarter
ATOSSA THERAPEUTICS INC. ( ATOS ) has 5 million of liabilities due within 12 months, and long term debt 0 as of last quarter
ATOSSA THERAPEUTICS INC. ( ATOS ) has 125 common shares outstanding as of last quarter
ATOSSA THERAPEUTICS INC. ( ATOS ) has 0 million USD of preferred stock value
Academic Scores:
ATOSSA THERAPEUTICS INC. ( ATOS ) Altman Z-Score is 10.14 as of last quarter
ATOSSA THERAPEUTICS INC. ( ATOS ) Piotroski Score is 3.00 as of last quarter
Corporate Governance:
ATOSSA THERAPEUTICS INC. ( ATOS ) largest shareholder is owning shares at 0.00 ($MM) value
Finn Jonathan(an insider) Bought 25000 shares of ATOSSA THERAPEUTICS INC. ( ATOS ) for the amount of $44250.00 on 2024-04-10
0.06% of ATOSSA THERAPEUTICS INC. ( ATOS ) is held by insiders, and 28.16% is held by institutions
ATOSSA THERAPEUTICS INC. ( ATOS ) went public on 2012-11-08
Other ATOSSA THERAPEUTICS INC. ( ATOS ) financial metrics:
FCF:-19.57
Unlevered Free Cash Flow:-20.76
EPS:-0.23
Operating Margin:-39472.22
Gross Profit Margin:-22.22
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-39.25
Beta:1.62
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About ATOSSA THERAPEUTICS INC. ( ATOS ) :
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201 for lung injury caused by cancer treatment. In addition, the company develops immunotherapy/chimeric antigen receptor therapy programs. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.